depression

9511213674_31a3c06cc7_z

Introduction

Clinical, unipolar depression is more than just feeling low for a day or two.

Depression is characterised as episodes of sadness, loss of interest and pleasure, often including feelings of low self-worth. Depression can also include a range of physiological symptoms, such as fatigue, pain, diminished appetite, lack of interest in sex, disturbed sleep, and poor concentration.

The World Health Organisation estimates that, globally, as many as 350 million people are affected at any given time, with one person in 20 reporting an episode of depression in a 12 month period (in a global sample of 17 countries). They describe depression as the leading cause of disability worldwide.

What we know already

We know that, despite the considerable global burden of depression, not everybody receives treatment, with figures ranging from 50% to 10% in less developed countries.

Evidence suggests that combined psychological and pharmacological treatments seem to work well. Broadly, we know that psychotherapies work in many cases – but not every time. We know that neurochemical factors, such as serotonergic dysfunction, play an important role in depression, which goes a long way in explaining the efficacy of SSRI treatments.

We also know that depression has a nasty habit of recurrence, and some psychological interventions, such as Mindfulness-Based Cognitive Therapy (MBCT) is recommended particularly for people who have experienced multiple episodes of depression, but not are currently severely depressed.

We know that people living with chronic physical illness are more likely to experience depression, and this combination is linked with poorer clinical outcomes.

Importantly though, we know that people with depression can still enjoy themselves, and a common misconception in depression is that people feel totally awful all of the time.

Areas of uncertainty

There is much still to determine. For example, we know that depression is hereditable, however the extent of heredity versus environmental influences are unclear.

We are also unsure as to the precise mechanisms that determine those who respond best to treatments, be they psychopharmacological, or psychological, or both.

What’s in the pipeline?

Despite advances in our understanding of depression, and how it is treated, it remains a highly recurrent difficulty, with many people not achieving complete remission between episodes.

Preventative interventions, either physiological, or psychological, may improve people’s resilience to depression, particularly those identified as being highly prone.

References

Cuijpers, P. (2015). Psychotherapies for adult depression: recent developments. Current Opinion in Psychiatry, 28, 24-29. [Abstract]

Naylor, C., Parsonage, M., McDaid, D., Knapp, M., Fossey, M. and Galea, A. (2012) Long-term conditions and mental health: the cost of co-morbidities. The King’s Fund, London, UK [PDF]

World Health Organisation (2015).Factsheet 369: Depression [Link]

Photo Credits

Sascha Kohlmann CC BY 2.0

Acknowledgement

Written by: Patrick Kennedy-Williams
Reviewed by:
Last updated: Nov 2015
Review due: Sep 2016

Our depression Blogs

Structured exercise reduces depression in older people, according to new systematic review

shutterstock_88371109

Regular readers of the Mental Elf will recall the blogs (Here is the evidence for exercising if you are depressed and New Cochrane review shows that exercise helps with depression) I wrote back in June and July about the evidence for exercising if you have depression. A new systematic review was published in the British [read the full story…]

How should we personalise treatment for adults with depression?

shutterstock_65982793

One of the criticisms that health professionals sometimes make of evidence-based research is that individual studies or reviews do not apply to the specific patient they are caring for. Of course, each patient is unique with their own values and preferences, as well as their own particular clinical characteristics, genetic make-up, biological markers and sociodemographic [read the full story…]

Modular psychotherapy may be the answer for young people with comorbid depression, anxiety and conduct problems

shutterstock_46723507

Young people with mental health problems often suffer from comorbidity, i.e. a complex mix of different conditions like depression, anxiety and conduct problems. Clinical research very often investigates specific treatments (e.g. CBT) for single disorders (e.g. depression) and guidelines and manuals are then developed for clinicians to help them treat these individual conditions. The problem [read the full story…]

Guest blog: Antidepressants and the Long Shadow of Stigma

shutterstock_46643248

Following the media coverage of the NHS statistics published last week that reported a large rise in antidepressant prescribing, Martin Brunet (a GP from Surrey and author of the excellent Binscombe Doctor Blog) has written an opinion piece that explores the positive and negative aspects of this complex story: “Are GPs prescribing antidepressants too readily?” [read the full story…]

The cost of antidepressant prescribing has risen by nearly a quarter in the last year, according to new NHS figures

shutterstock_68419474

The largest annual rise in prescriptions was seen in antidepressants according to figures published this week by the NHS Information Centre. 46.7 million prescriptions for antidepressants were dispensed in 2011, a rise of 3.9 million on 2010. This equates to a rise of 9.1% in the 12 month period, which is similar to that seen [read the full story…]

The dose-response association between psychological distress and mortality, new BMJ meta-analysis shows the link

shutterstock_108547067

There is an increasing body of evidence showing that depression and anxiety are linked with other health conditions like cancer and cardiovascular disease. I’ve blogged about the link between depression and stroke, and there are a number of other studies that show an association between psychological distress (the symptoms of depression and anxiety) and mortality, [read the full story…]

Treating depression and anxiety with the benzodiazepine alprazolam: new Cochrane review recommends caution

shutterstock_62127079

Antidepressants and psychotherapies are the mainstay for treating depression, but another option is the benzodiazepine drug alprazolam, which is recommended for treating depression when anxiety is also involved. Some doctors prescribe a short course of benzodiazepines to help depressed and anxious patients, but this is not supported by NICE guidance. High-potency tranquillisers like alprazolam are [read the full story…]

Can online fantasy games help young people overcome depression?

shutterstock_77231779

Computerised cognitive behavioural therapy is a popular topic for research at the moment. We’ve seen a number of systematic reviews and large scale trials published over recent years, but the vast majority focus on adults with depression, so it’s hard to know how applicable the results are to adolescents. Of course, most young people are [read the full story…]

Can vitamin D supplementation help relieve the symptoms of depression?

shutterstock_100738351

This week in The British Journal of Psychiatry, researchers in Norway have published results from their randomised controlled trial studying the effects of vitamin D on depressive symptoms in otherwise healthy adults. The study, directed by Dr Marie Kjaergaard and a team of doctors out of the University Tromsø in Norway, found that vitamin D [read the full story…]

Citalopram outperforms all other antidepressants except escitalopram for acute phase depression, according to new review

shutterstock_87213745

Citalopram (brand names: Cipramil and Celexa) is an antidepressant drug in the selective serotonin reuptake inhibitor (SSRI) class. It was one of the first SSRIs to come onto the market over 20 years ago and is available as tablets and as oral drops that are taken in a juice drink. There are lots of antidepressants [read the full story…]